Year in Review: Dr. P Seo Novel PsA therapy on the horizon: ⭐️Brepocitinib ➡️ Tyk-2 inhibitor: IL12/23 & t
Tweet Content
Year in Review: Dr. P Seo
Novel PsA therapy on the horizon:
⭐️Brepocitinib
➡️ Tyk-2 inhibitor: IL12/23 & type I IFN
➡️ Phase Ib, 218 pts, 8% TNFi failure
➡️ 71% on concurrent MTX
➡️ Wk 16: ACR 50/70 & PASI75/90 improved, maintained through week 52
#ACR23 @RheumNow
Show on Archive Page
On
Display in Search Results
On
PDQ
Off